Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTNFR:Fc for active ankylosing spondylitis (Phase III, placebo-controlled)
CTR20140351Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of etanercept in ankylosing spondylitis (AS), sponsored by Qilu Pharmaceutical. Started May 2014; status: active.
02
Drugs
etanercept
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20140351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140351.